The official word on BPC-157
If you have been following the news on BPC-157, you know the rules have been shifting. As of September 2026, it is currently in FDA Category 2, which means the FDA has identified potential safety risks. These include immunogenicity (your immune system reacting to the peptide), impurities, and a general lack of human safety data.
In July 2026, the Pharmacy Compounding Advisory Committee reviewed it for the 503A Bulks List, which is the official list of substances allowed for personalized compounding. For now, it is not listed on the 503B Bulks List, and regulators have previously issued warning letters to companies like Tailor Made Compounding regarding its use.
The latest on Semaglutide and GLP-1s
Semaglutide (found in approved products like Wegovy and Ozempic) has moved out of its national shortage period. This means the rules for compounding it have tightened. The FDA has noted that semaglutide sodium and semaglutide acetate are not the same as the active ingredients in approved drugs, and they aren't aware of a lawful way to use those salt forms in compounding.
On the safety side, researchers are watching a few signals. While nausea and vomiting are common, there are emerging reports of NAION (an eye condition) and pulmonary aspiration (breathing foreign material into the lungs), which is a concern for people undergoing anesthesia.
Why are some peptides being restricted?
Several other compounds have landed in Category 2, often because the FDA is worried about immunogenicity or a lack of safety information. These include:
- GHRP-2 and GHRP-6: Both are in Category 2 due to immune response concerns.
- Melanotan II: This one has safety warnings from both the FDA and the Australian TGA due to multiple serious side effects.
- KPV: Its nomination was recently withdrawn and it was reviewed by the advisory committee in July 2026.
- MK-677: Though it is a small molecule rather than a peptide, it was placed in Category 2 in both 2022 and 2023.
What about clinical trials?
Scientists are still working on these—turns out the human body is complicated. Who knew? While Semaglutide showed a 14.9% weight loss in the STEP 1 trial, other trials have different results. For example, a Phase III trial for Thymosin Alpha 1 in sepsis was negative, showing no reduction in mortality.
This is a great one to bring up with your doctor. You can find peptide-experienced physicians in our Find a Doctor directory. If you are curious about semaglutide or bpc-157, we have more data on their specific pages.
How to stay safe
Regulations change fast, and it is important to know how to find a peptide prescriber who stays on top of these updates. Because rules vary by location and provider, you should always check the current status of a compound before starting. You can search for qualified experts through our Find a Doctor resource to ensure you are getting the most recent information.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.